New DRG in MDC12 for outpatient stereotactic radiotherapy or demanding isotope therapy cases
|Target version:||Expert Group 2017|
|MDC:||MDC12||Owner / responsible:||National organisations|
|Target Grouper:||FIN||Old forum status:|
DRG 912A Male reproductive system tumor, radiotherapy, short therapy in Finnish grouper is meant for cases of male reproductive tumor treated with radiotherapy. It includes four different groups of procedures: radiotherapy (PROCPROP 90T05), radiotherapy with large shaped fields (90T06), stereotactic radiotherapy or demanding isotope therapy (90T07), special demanding isotope therapy (90T08).
The number of cases in 912A is high (ca 27 000 in 2014 and ca 31 000 in 2015), so is the variation coefficient, 182% and 201% respectively. That was the indication for further analysis.
The mean cost of DRG 912A is 175 EUR in 2014 and 193 in 2015 ranging between 30 and 5 820 EUR, and 30 and 14 889 EUR respectively.
The cases with PROCPROP 90T07 differ from the rest of the group and have the mean cost ca ten times higher compared to the DRG 912A average, i.e. 193 EUR vs ca 1 800 EUR in 2015.
Also the variation coefficient of cases with PROCPROP 90T07 is much lower than all cases in DRG 912A (34% versus 201% in 2015) and shows the cost homogeneity of selected cases.
Based on the cost analysis we suggest create separate DRG for outpatient cases with PROCPROP 90T07.
The cases with main diagnosis from MDC12 and procedure code with PROCPRO 90T07 will be grouped in a new DRG 912C.
Name of the new DRG should be Male reproductive system tumor, stereotactic radiotherapy or demanding isotope therapy, short therapy.
Appendix 2. The technical changes may contain mistakes and have to be used with caution.
Appendix 1. Cost analysis is based on five university hospital data of 2015, grouped with Finnish 2017 grouper, and data of 2014, grouped with Finnish 2016 grouper.
#1 Updated by Kristin Dahlen over 4 years ago
- File Case 507_Norwegian DRG solution.xlsx added
In Norway we have already implemented a split for this cases.
DRG 852N Brachyterapy for prostate cancer (covers both inpatient and outpatient cases) and DRG 852X Brachyterapy for tumor, outpatient.
This DRGs are part of a logic concerning both the radiotherapy and the planning of radiotherapy.
See the enclosed excel sheet for the Norwegian DRG logic.